Case Finding for Coeliac Disease Using a Point of Care Test in a Pharmacy Setting
Primary Purpose
Coeliac Disease
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Simtomax
Sponsored by
About this trial
This is an interventional diagnostic trial for Coeliac Disease focused on measuring Point of care test, Diagnosis, Case finding
Eligibility Criteria
Inclusion Criteria:
- Age 18 or over, and
Purchasing gastrointestinal medications, including:
- Over the counter medications (i.e. medicines purchasable without a prescription or supervision of a pharmacist)
- Pharmacy medications (i.e. medicines purchasable from a pharmacy without a prescription but provided under the supervision of a pharmacist. These medicines are kept 'behind the counter' and are not available on the pharmacy shelves.)
- Prescription only medications (i.e. medicines only available with a prescription that is issued by a GP or another suitably qualified healthcare professional), and/ or
Suffering from any of the following:
- Persistent unexplained abdominal or gastrointestinal symptoms
- Prolonged fatigue
- Unexpected weight loss
- Severe or persistent mouth ulcers
- Unexplained iron, vitamin B12 or folate deficiency
- Type 1 diabetes
- Autoimmune thyroid disease
- Irritable bowel syndrome
- Metabolic bone disorder (reduced bone mineral density or osteomalacia)
- Unexplained neurological symptoms (particularly peripheral neuropathy or ataxia)
- Unexplained subfertility or recurrent miscarriage
- Persistently raised liver enzymes
- Dental enamel defects, and/ or 4 Have first degree relatives with coeliac disease
Exclusion Criteria:
- previous diagnosis of coeliac disease, or
- previous or current investigation for coeliac disease.
- age under 18.
Sites / Locations
- Sheffield Teaching Hospitals
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
coeliac disease point of care test
Arm Description
Patients will be consented for a finger prick point of care test, Simtomax, at the pharmacy.
Outcomes
Primary Outcome Measures
The prevalence of CD in this study cohort as a result of a case finding approach using a POCT in a pharmacy setting.
This feasibility study will describe the prevalence of CD in this study cohort. This will be compared to the established prevalence of CD of 1% in the general population.
Secondary Outcome Measures
The proportion of individuals agreeing to fill in the eligibility questionnaire.
The proportion of individuals undertaking the POCT.
The proportion of individuals undergoing a gastroscopy with duodenal biopsies.
Full Information
NCT ID
NCT02675283
First Posted
January 25, 2016
Last Updated
November 22, 2017
Sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
1. Study Identification
Unique Protocol Identification Number
NCT02675283
Brief Title
Case Finding for Coeliac Disease Using a Point of Care Test in a Pharmacy Setting
Official Title
Case Finding for Coeliac Disease Using a Point of Care Test in a Pharmacy Setting: A Feasibility Study
Study Type
Interventional
2. Study Status
Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
July 2016 (Actual)
Primary Completion Date
October 2017 (Actual)
Study Completion Date
October 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study aims to assess whether it is feasible to use a point of care test to increase the detection of coeliac disease in a pharmacy setting.
Detailed Description
Coeliac disease (CD) is an autoimmune condition characterised by mucosal damage of the small intestine by dietary gluten. CD affects 1 in 100 people. However, patients do not always have symptoms, resulting in 5 undiagnosed patients to every known case of CD. Undiagnosed CD can lead to complications such as vitamin and mineral deficiencies, osteoporosis and small bowel lymphoma, as well as impairing quality of life.
Currently, patients are diagnosed with a conventional blood test for coeliac antibodies (anti-TTG) as a first line test. Simtomax®, a new coeliac point of care test (POCT), has become available. It is a finger prick test that provides results of a coeliac antibody, deaminated gliadin peptide, within 10 minutes. Studies showed that Simtomax is as accurate as anti-TTG, with a 92.7% chance of detecting CD and 98.7% chance of ruling out CD.
This study aims to assess whether the POCT can increase the detection of adult coeliac disease when used in a pharmacy setting. A feasibility study using a case-finding approach will be conducted at 5 pharmacies in Sheffield over 20 months. It will be funded by Professor Sanders' research funds.
Customers who enter the pharmacies will be approached by the principal investigator (PI). Eligible participants (those with symptoms suggestive of or risk factors for CD) will be consented for the POCT by the PI. The POCT will be carried out at the pharmacies. Any participant with a positive test will be advised to see his GP to be referred for a gastroscopy at the Royal Hallamshire Hospital to confirm the diagnosis. Once diagnosed, the participant will follow the standard management pathway for any patients with CD.
Results of the study will be compared to the established prevalence of CD of 1%, to assess whether using POCT in a pharmacy setting can increase the detection of adult CD.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coeliac Disease
Keywords
Point of care test, Diagnosis, Case finding
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
502 (Actual)
8. Arms, Groups, and Interventions
Arm Title
coeliac disease point of care test
Arm Type
Other
Arm Description
Patients will be consented for a finger prick point of care test, Simtomax, at the pharmacy.
Intervention Type
Device
Intervention Name(s)
Simtomax
Other Intervention Name(s)
Point of care test
Intervention Description
Patients will undertake a finger prick point of care test, Simtomax, at the pharmacy. A sample of 25 μl of capillary venous blood is required which can be obtained through a simple finger prick technique. The sample is then applied to the test device, followed by the application of 5 drops of the provided buffer solution. The result can be read after 10 minutes. Positive results are indicated by the presence of a solid red line, with a single line for a combined IgA and IgG DGP positivity, and a single line for the presence of total IgA. An in-built control line ensures a correctly functioning test.
Primary Outcome Measure Information:
Title
The prevalence of CD in this study cohort as a result of a case finding approach using a POCT in a pharmacy setting.
Description
This feasibility study will describe the prevalence of CD in this study cohort. This will be compared to the established prevalence of CD of 1% in the general population.
Time Frame
Baseline - 20 months
Secondary Outcome Measure Information:
Title
The proportion of individuals agreeing to fill in the eligibility questionnaire.
Time Frame
Baseline - 20 months
Title
The proportion of individuals undertaking the POCT.
Time Frame
Baseline - 20 months
Title
The proportion of individuals undergoing a gastroscopy with duodenal biopsies.
Time Frame
Baseline - 20 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age 18 or over, and
Purchasing gastrointestinal medications, including:
Over the counter medications (i.e. medicines purchasable without a prescription or supervision of a pharmacist)
Pharmacy medications (i.e. medicines purchasable from a pharmacy without a prescription but provided under the supervision of a pharmacist. These medicines are kept 'behind the counter' and are not available on the pharmacy shelves.)
Prescription only medications (i.e. medicines only available with a prescription that is issued by a GP or another suitably qualified healthcare professional), and/ or
Suffering from any of the following:
Persistent unexplained abdominal or gastrointestinal symptoms
Prolonged fatigue
Unexpected weight loss
Severe or persistent mouth ulcers
Unexplained iron, vitamin B12 or folate deficiency
Type 1 diabetes
Autoimmune thyroid disease
Irritable bowel syndrome
Metabolic bone disorder (reduced bone mineral density or osteomalacia)
Unexplained neurological symptoms (particularly peripheral neuropathy or ataxia)
Unexplained subfertility or recurrent miscarriage
Persistently raised liver enzymes
Dental enamel defects, and/ or 4 Have first degree relatives with coeliac disease
Exclusion Criteria:
previous diagnosis of coeliac disease, or
previous or current investigation for coeliac disease.
age under 18.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Sanders
Organizational Affiliation
Sheffield Teaching Hospitals NHS Foundation Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sheffield Teaching Hospitals
City
Sheffield
ZIP/Postal Code
S10 2JF
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Case Finding for Coeliac Disease Using a Point of Care Test in a Pharmacy Setting
We'll reach out to this number within 24 hrs